Gilead Sciences

Latest Headlines

Latest Headlines

States limit access to hep C meds amid pricing battle

As hep C drugmakers such as Gilead Sciences and AbbVie continue to duke it out for dominance, there is one piece of the market both sides are battling to claim: state Medicaid programs.

Gilead's huge Sovaldi payoff yields a nice 23% pay hike for CEO

For several years, Gilead Sciences CEO John Martin has collected annual compensation worth about $15 million and his stock gains since 2009 run into the hundreds of millions. But for a record-smashing year that vaulted his company into the ranks of the global top 10, Martin snared a comparatively small payoff in 2015.

Cipla revs up for generic Sovaldi launch in India

Cipla is rolling out a low-cost version of Gilead Sciences' hep C powerhouse Sovaldi in India, the latest company to launch a copycat of the drug as part of Gilead's deal with generic drugmakers to provide Sovaldi at cut-rate prices.

Hep C meds cost-effective, but affordable? With new 46% discounts, maybe

When hepatitis C drugmakers started wooing payers with discounts, the cost cuts made the difference between an overwhelming burden and cost-effective spending. So say two new studies looking at the cost of treating the disease with a new generation of quite effective--but very expensive--treatments.

First off the blocks, Natco gets India's regulatory nod for hep C copy

India's Natco Pharma said that it has received Indian regulatory approval to locally sell its generic version of Sovaldi, the hepatitis C treatment that costs $1,000 a day in the U.S., making it the first Indian license holder to do so and allowing it to set a bar on pricing in India and onto emerging markets.

Whack-a-mole begins as Natco Sovaldi copies sprout in Nepal, Bangladesh

Want Sovaldi (sofosbuvir), the hepatitis C drug selling in the United States for $1,000 per pill, for just $10 a pill? Go to Bangladesh or some other country where the drug is about to be produced and sold free of the control of Sovaldi's owner, Gilead Sciences.

Gilead moves from Japan to India lining up hep C, HIV licensing deals

Gilead Sciences has been busy in India and Japan signing licensing agreements for at least four of its drugs.

Gilead looks overseas to guard Sovaldi profits from taxes

Tax inversion deals are not the only trick Big Pharma has up its sleeve to avoid steep U.S. taxes. Gilead Sciences is booking profits overseas in low-tax countries to take home more profits for its blockbuster hep C drug Sovaldi.

Gilead's hep C star Harvoni, BMS' cancer med Opdivo lead ranks of 'exciting' launches

Which launches are the ones to watch? That can vary depending on who you're talking to. But as Bloomberg Intelligence recently found, industry members and healthcare investors have some similar ideas this year--and unsurprisingly, they've got their eyes on Gilead's Harvoni.

UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance

In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.